Sammy,
Aside from Sarepta's sketchy FDA approval - without real efficacy data - one other big criticism about Exondys51 is it only treats 13% of boys.
Even with Gene Therapy, we see both Pfizer and Sarepta exclude boys with certain mutations from their program.
Taking the emotion away - looking from the outside - one can see why Sarepta might want to partner with ANP.
...access to 100% of DMD population - USA only - also secure ATL1102 for LGMD too.
$250m per indication + equity position.
Makes perfect sense.
.
- Forums
- ASX - By Stock
- Older data but interesting ..MS summary
Sammy, Aside from Sarepta's sketchy FDA approval - without real...
-
- There are more pages in this discussion • 36 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PER (ASX) to my watchlist
|
|||||
Last
8.4¢ |
Change
0.003(3.70%) |
Mkt cap ! $75.73M |
Open | High | Low | Value | Volume |
8.1¢ | 8.4¢ | 8.1¢ | $79.19K | 960.1K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 100200 | 8.1¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
8.4¢ | 114242 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 100200 | 0.081 |
6 | 48604 | 0.080 |
2 | 121300 | 0.077 |
1 | 130000 | 0.076 |
3 | 173335 | 0.075 |
Price($) | Vol. | No. |
---|---|---|
0.084 | 114242 | 2 |
0.085 | 4326 | 1 |
0.087 | 125000 | 1 |
0.089 | 102263 | 2 |
0.090 | 153175 | 2 |
Last trade - 16.10pm 25/06/2024 (20 minute delay) ? |
Featured News
PER (ASX) Chart |